A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance (Q38127171)

29 August 2017

title

A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance (English)

1 reference

29 August 2017

1 reference

1 reference

L van der Tol

1 reference

29 August 2017

B E Smid

1 reference

29 August 2017

B J H M Poorthuis

1 reference

29 August 2017

M Biegstraaten

1 reference

29 August 2017

R H Lekanne Deprez

1 reference

29 August 2017

G E Linthorst

1 reference

29 August 2017

C E M Hollak

1 reference

29 August 2017

language of work or name

English

0 references

publication date

6 August 2013

1 reference

Journal of Medical Genetics

29 August 2017

published in

1 reference

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

page(s)

1-9

1 reference

Prevalence of lysosomal storage disorders

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

The frequency of lysosomal storage diseases in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Natural history of Fabry disease in females in the Fabry Outcome Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

High incidence of later-onset fabry disease revealed by newborn screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

LC-MS/MS analysis of plasma lyso-Gb3 in Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Plasma globotriaosylsphingosine as a biomarker of Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Fabry disease: biochemical, pathological and structural studies of the α-galactosidase A with E66Q amino acid substitution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Angiokeratoma: a cutaneous marker of Fabry’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Sarcomere Protein Gene Mutations in Patients With Apical Hypertrophic Cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Results of an ophthalmologic screening programme for identification of cases with Anderson-Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Glycogen storage diseases presenting as hypertrophic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Screening for Fabry disease in patients with left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Prevalence and cardiovascular features of Japanese hemodialysis patients with Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Frequency of Fabry disease in male and female haemodialysis patients in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Significance of screening for Fabry disease among male dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Serum Globotriaosylceramide Assay as a Screening Test for Fabry Disease in Patients with ESRD on Maintenance Dialysis in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Implementation of high-throughput screening for Fabry disease in Toronto dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Two-tier approach for the detection of alpha-galactosidase A deficiency in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study--screening genetic conditions in Portuguese young stroke patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Fabry disease in unselected patients with TIA or stroke: population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Zurich Fabry study - prevalence of Fabry disease in young patients with first cryptogenic ischaemic stroke or TIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Frequency of Fabry disease in patients with small-fibre neuropathy of unknown aetiology: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Newborn screening for lysosomal storage disorders in hungary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Multifocal white matter lesions associated with the D313Y mutation of the α-galactosidase A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Drug-induced corneal complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

The relation between small nerve fibre function, age, disease severity and pain in Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Early cerebral manifestations in a young female with Fabry disease with skewed X-inactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

X-inactivation in Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the α-galactosidase A gene in the Czech and Slovak population

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJMEDGENET-2013-101857

Failure to detect Fabry patients in a cohort of prematurely atherosclerotic males

21 January 2018

1 reference

9 November 2024

https://opencitations.net/index/api/v1/citations/10.1007/S10545-007-0721-9

Identifiers

DOI

10.1136/JMEDGENET-2013-101857

1 reference

29 August 2017

1 reference